STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. The company operates in two segments, Generics and Branded Products. The Generics segment provides various active ingredients, including Omeprazole and Pantoprazol, the stomach medicines; Phospholipide, a liver medicine; Enalapril, an ACE inhibitor; and Diclofenac, an antirheumatic drug. The Branded Products segment provides non-prescription products comprising Grippostad, a cold medicine; Apo-Go, a Parkinson medicine; Hirudoid, a venous therapeutic agent; Chondroxid for the treatment of degenerative joint diseases; and Levomecol, a topical antibiotic. The company has license and collaboration agreements with Gedeon Richter Plc for the development and marketing of biosimilar products for monoclonal antibodies Rituximab and optionally Trastuzumab. It serves patients and/or consumers, doctors, doctors’ cooperatives, pharmacies, pharmacy co-operatives, hospitals, wholesalers, and other service providers in the health care market, as well as public health insurance organizations or private insurances. STADA Arzneimittel Aktiengesellschaft was founded in 1895 and is based in Bad Vilbel, Germany.

Key Statistics